Scholarlink

Objective <p>The aim of this study is to investigate the status and significantly influencing factors of treatment and prognosis perceptions among primary bone marrow lymphoma (PBML) patients.</p> Methods <p>We analyzed the clinical manifestations of 30 PBML patients with different treatment regimen and evaluated prognosis using the International Task Force Response Criteria for Malignant lymphoma to identify the major factors influencing prognosis and the best treatment for PBML.</p> Results <p>In this retrospective cohort study of 30 newly diagnosed PBML patients, we demonstrated a significantly poorer prognosis compared to individuals with nodal malignant lymphoma. The median overall survival (OS) was 9 months and the median progression free survival (PFS) was 6.5 months. Univariate analysis identified subnormal platelet levels (<i>P</i> = 0.005) and failure to attain at least partial remission following four treatment cycles (<i>P</i> = 0.001) as significant predictors of unfavorable prognosis. Multivariate analysis demonstrated that remission status after four treatment cycles had prognostic significance. Patients who achieved complete remission had significantly longer median PFS and OS compared to those with partial remission (PFS: 34.5 months vs. 20.5 months; OS: 41.5 vs. 23 months). In patients with diffuse large B-cell lymphoma (DLBCL), the R-DA-EPOCH regimen demonstrated high efficacy; conversely, the R-CHOP protocol showed superior effectiveness in B-chronic lymphoproliferative disorder (B-CLPD) cases.</p> Conclusion <p>PBML patients have a poor prognosis, and individual response to treatment may serve as a prognostic factor.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A Retrospective Analysis of Primary Bone Marrow Lymphoma: Clinical Features and Prognostic Factors

  • 期刊论文

  • 发表日期：

    2025年4月25日

查看全文
  • Shuang Gao,
  • Lin Chen,
  • Su Liu,
  • Jing Ma,
  • Li Lin,
  • Zhiying Zhang,
  • Zeng Cao,
  • Qian Li

摘要

Objective

The aim of this study is to investigate the status and significantly influencing factors of treatment and prognosis perceptions among primary bone marrow lymphoma (PBML) patients.

Methods

We analyzed the clinical manifestations of 30 PBML patients with different treatment regimen and evaluated prognosis using the International Task Force Response Criteria for Malignant lymphoma to identify the major factors influencing prognosis and the best treatment for PBML.

Results

In this retrospective cohort study of 30 newly diagnosed PBML patients, we demonstrated a significantly poorer prognosis compared to individuals with nodal malignant lymphoma. The median overall survival (OS) was 9 months and the median progression free survival (PFS) was 6.5 months. Univariate analysis identified subnormal platelet levels (P = 0.005) and failure to attain at least partial remission following four treatment cycles (P = 0.001) as significant predictors of unfavorable prognosis. Multivariate analysis demonstrated that remission status after four treatment cycles had prognostic significance. Patients who achieved complete remission had significantly longer median PFS and OS compared to those with partial remission (PFS: 34.5 months vs. 20.5 months; OS: 41.5 vs. 23 months). In patients with diffuse large B-cell lymphoma (DLBCL), the R-DA-EPOCH regimen demonstrated high efficacy; conversely, the R-CHOP protocol showed superior effectiveness in B-chronic lymphoproliferative disorder (B-CLPD) cases.

Conclusion

PBML patients have a poor prognosis, and individual response to treatment may serve as a prognostic factor.